NYSE Euronext (NYX) today announced trading volumes for its
global derivatives and cash equities exchanges for November 20121.
Global derivatives average daily volume (“ADV”) of 8.1 million
contracts in November 2012 decreased 2.5% compared to November
2011, but increased 12.2% from October 2012. Trading volumes in
European and U.S. equities, declined year-over-year but U.S
equities improved from October 2012 levels.
Highlights
- NYSE Euronext global derivatives ADV in
November 2012 of 8.1 million contracts decreased 2.5% compared to
November 2011 but increased 12.2% from October 2012 levels.
- NYSE Euronext European derivatives
products ADV in November 2012 of 4.0 million contracts increased
0.2% compared to November 2011, and increased 26.8% from October
2012 levels. Excluding Bclear, NYSE Liffe's trade administration
and clearing service for OTC products, European derivatives
products ADV decreased 24.6% compared to November 2011 but
increased 2.3% from October 2012.
- NYSE Euronext U.S. equity options (NYSE
Arca and NYSE Amex) ADV of 4.1 million contracts in November 2012
decreased 4.2% compared to November 2011 levels, but increased by
0.7% from October 2012 levels. NYSE Euronext’s U.S. options
exchanges accounted for 28.1% of total U.S. consolidated equity
options trading in November 2012, unchanged from the prior month
and down only slightly from last month’s record high.
- NYSE Liffe U.S. ADV of approximately
51,500 contracts decreased from 88,500 contracts in November 2011,
but increased from 43,700 contracts in October 2012.
- NYSE Euronext European cash products
ADV of 1.2 million transactions in November 2012 decreased 30.0%
compared to November 2011 and decreased 8.5% compared to October
2012.
- NYSE Euronext U.S. cash products (NYSE,
NYSE Arca and NYSE Amex) handled ADV of 1.6 billion shares in
November 2012 decreased 24.8% compared to November 2011 but
increased 3.2% compared to October 2012. NYSE Euronext’s Tape A
matched market share in November 2012 was 31.7%, down from 34.1% in
November 2011, but up from 30.6% in October 2012.
Derivatives Trading
European Derivatives
- NYSE Euronext European derivatives
products ADV in November 2012 was 4.0 million futures and options
contracts, an increase of 0.2% from November 2011 and an increase
of 26.8% from October 2012.
- The 4.0 million in European derivatives
futures and options contracts ADV in November 2012 consisted of 2.4
million contracts executed through our full-service LIFFE CONNECT
trading platform and 1.6 million contracts, or 40.9%, executed
through Bclear, NYSE Liffe's trade administration and clearing
service for OTC products. Excluding Bclear, European derivatives
products ADV decreased 24.6% compared to November 2011, but
increased 2.3% from October 2012.
- Year-to-date, European derivatives
products ADV of 3.7 million contracts was 18.0% below prior year
levels. The 3.7 million in futures and options contracts ADV
year-to-date consisted of 3.6 million contracts executed through
LIFFE CONNECT trading platform and 1.1 million contracts, or 30.0%,
executed through Bclear.
- Total fixed income products ADV of 1.6
million contracts in November 2012 decreased 25.9% from November
2011 but increased 3.9% from October 2012. Year-to-date, total
fixed income products ADV of 1.8 million contracts was 24.1% below
prior year levels.
- Total equity products (including
Bclear) ADV of 2.3 million contracts in November 2012 increased
30.8% compared to November 2011 and increased 53.2% from October
2012. The 2.3 million contracts in equity products ADV consisted of
1.9 million contracts in individual equity products ADV and 0.4
million contracts in equity index products ADV. The 1.9 million
contracts in individual equity products ADV consisted of 1.5
million in futures contracts, which represented a 115.3% increase
compared to November 2011 and 0.4 million in options contracts,
which represented a 31.8% decrease compared to November 2011.
Year-to-date, total equity products ADV of 1.9 million contracts
were 12.5% below prior year levels.
- Total commodities products ADV of
86,000 contracts in November 2012 increased 26.2% compared to
November 2011, but decreased 18.5% compared to October 2012.
Year-to-date, total commodities product ADV of 89,000 contracts was
8.3% above prior year levels.
U.S. Derivatives
- NYSE Euronext U.S. equity options (NYSE
Arca and NYSE Amex) ADV of 4.1 million contracts in November 2012
decreased 4.2% compared to November 2011, but increased 0.7%
compared to October 2012. Year-to-date, U.S. equity options ADV of
3.9 million contracts was 12.5% below prior year levels.
- Total U.S. consolidated equity options
ADV decreased 4.2% to 14.5 million contracts in November 2012
compared to November 2011 but increased 2.1% compared to October
2012. Year-to-date, U.S. consolidated equity options ADV of 14.8
million contracts was 13.1% below prior year levels.
- NYSE Euronext’s U.S. options exchanges
accounted for 28.1% of the total U.S. consolidated equity options
trading in November 2012, in line with 28.1% in November 2011, but
down slightly from a record 28.5% in October 2012. NYSE Euronext
was the #1 options exchange in terms of market share for the second
consecutive month.
- NYSE Liffe U.S. ADV of approximately
51,500 contracts decreased from 88,500 contracts in November 2011,
but increased from 43,700 contracts in October 2012. Year-to-date,
U.S. futures and futures options ADV of 72,800 contracts was 9.5%
below prior year levels.
Cash Trading
European Cash
- NYSE Euronext European cash products
ADV of 1.2 million transactions in November 2012 decreased 30.0%
compared to November 2011 and decreased 8.5% compared to October
2012.
- Year-to-date, European cash products
ADV of 1.5 million transactions was 15.4% below prior year
levels.
U.S. Cash
- NYSE Euronext U.S. cash products
handled ADV in November 2012 decreased 24.8% to 1.6 billion shares
compared to November 2011 but increased 3.2% from October
2012.
- Year-to-date, U.S. cash products
handled ADV was 1.7 billion shares, down 27.0% from prior year
levels.
- NYSE Euronext’s Tape A matched market
share in November 2012 was 31.7%, down from 34.1% in November 2011,
but up from 30.6% in October 2012.
Exchange Traded Funds
- NYSE Euronext U.S. matched
exchange-traded funds ADV (included in volumes for Tape B and Tape
C) of 209 million shares in November 2012 decreased 34.9% compared
to November 2011, but increased 9.8% compared to October 2012.
- Year-to-date, NYSE Euronext U.S.
matched exchange-traded funds ADV of 212 million shares was 35.8%
below prior year levels.
Please click here for the Monthly Transaction Activity Data
Table.
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial
markets and provider of innovative trading technologies. The
company's exchanges in Europe and the United States trade equities,
futures, options, fixed-income and exchange-traded products. With
approximately 8,000 listed issues (excluding European Structured
Products), NYSE Euronext's equities markets - the New York Stock
Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca -
represent one-third of the world’s equities trading, the most
liquidity of any global exchange group. NYSE Euronext also operates
NYSE Liffe, one of the leading European derivatives businesses and
the world's second-largest derivatives business by value of
trading. The company offers comprehensive commercial technology,
connectivity and market data products and services through NYSE
Technologies. NYSE Euronext is in the S&P 500 index. For more
information, please visit:http://www.nyx.com.
Please follow us at:
Exchanges Blog
Facebook
LinkedIn
Twitter
Disclaimer and Cautionary Note Regarding Forward-Looking
Statements
This press release may contain forward-looking statements,
including forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include, but are not limited to,
statements concerning NYSE Euronext's plans, objectives,
expectations and intentions and other statements that are not
historical or current facts. Forward-looking statements are based
on NYSE Euronext's current expectations and involve risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such forward-looking statements.
Factors that could cause NYSE Euronext's results to differ
materially from current expectations include, but are not limited
to: NYSE Euronext's ability to implement its strategic initiatives,
economic, political and market conditions and fluctuations,
government and industry regulation, interest rate risk and U.S. and
global competition, and other factors detailed in NYSE Euronext's
2011 Annual Report on Form 10-K and other periodic reports filed
with the U.S. Securities and Exchange Commission or the French
Autorité des Marchés Financiers. In addition, these statements are
based on a number of assumptions that are subject to change.
Accordingly, actual results may be materially higher or lower than
those projected. The inclusion of such projections herein should
not be regarded as a representation by NYSE Euronext that the
projections will prove to be correct. This press release speaks
only as of this date. NYSE Euronext disclaims any duty to update
the information herein.
1 All NYSE Euronext derivatives transactions count buy and sell
orders together as a single transaction. NYSE Euronext European
equities transactions count each buy and sell order as separate
transactions, NYSE Euronext U.S. equities transactions count buy
and sell orders together as a single transaction.
NYSE
Euronext
Monthly Volume
Summary
Average Daily Volume
Total Volume Average Daily
Volume Total Volume
% Chg vs.
% Chg vs.
(Unaudited; contracts in thousands)
Nov-12 Nov-11 % Chg Nov-12
Nov-11 % Chg
YTD 2012
YTD 2011 YTD 2012
YTD 2011
Number of Trading Days - European Cash 22 22 22 22 237 237
Number of Trading Days - European Derivatives 22 22 22 22 238 238
Number of Trading Days - U.S. Markets 21 21 21 21 230 230
European Derivatives Products 3,983 3,974
0.2% 87,616 87,432 0.2% 3,737
-18.0% 889,477 -17.4% of which Bclear 1,630
855 90.6% 35,857 18,811 90.6% 1,103 -2.5% 262,605 -1.7%
Total Fixed Income Products 1,582 2,136
-25.9% 34,803 46,998 -25.9%
1,768 -24.1% 420,750 -23.5%
Short Term Interest Rate Products 1,376 1,963 -29.9% 30,267 43,195
-29.9% 1,613 -26.2% 383,910 -25.6% Medium and Long Term Interest
Rate Products 1 206 173 19.3% 4,537 3,803 19.3% 155 7.6% 36,840
8.5%
Total Equity Products 2 2,314
1,770 30.8% 50,914 38,930 30.8%
1,881 -12.5% 447,634 -11.7%
Individual Equity Products 1,884 1,240 52.0% 41,457 27,275 52.0%
1,407 -10.0% 334,756 -9.3% Futures 1,521 706 115.3% 33,454 15,539
115.3% 963 -0.4% 229,301 0.4% Options 364 533 -31.8% 8,003 11,737
-31.8% 443 -25.6% 105,456 -25.0% Equity Index Products 430 530
-18.9% 9,457 11,654 -18.9% 474 -19.0% 112,878 -18.3% of
which Bclear 1,630 855 90.6% 35,857 18,811 90.6% 1,103 -2.5%
262,605 -1.7% Individual Equity Products 1,556 787 97.7% 34,236
17,320 97.7% 1,030 -2.1% 245,169 -1.3% Futures 1,494 681 119.3%
32,872 14,987 119.3% 940 -1.1% 223,727 -0.2% Options 62 106 -41.5%
1,365 2,333 -41.5% 90 -11.9% 21,443 -11.2% Equity Index Products 74
68 8.8% 1,621 1,490 8.8% 73 -8.0% 17,435 -7.3%
Commodity
Products 86 68 26.2% 1,898
1,504 26.2% 89 8.3% 21,093
9.2% U.S. Derivatives Products
Equity Options 3 NYSE Euronext Options
Contracts 4,068 4,244 -4.2% 85,423 89,127 -4.2% 3,893 -12.5%
895,374 -12.9% Total Consolidated Options Contracts 14,488 15,119
-4.2% 304,256 317,497 -4.2% 14,767 -13.1% 3,396,328 -13.5%
NYSE Group Share of Total 28.1% 28.1% 28.1% 28.1% 26.4% 0.2% 26.4%
0.2%
NYSE Liffe U.S. Futures and Futures
Options Volume* 51.5 88.5 -41.8% 1,133 1,947 -41.8% 72.8 -9.5%
17,316.9 -9.1%
European Cash Products (trades in
thousands) 1,170 1,671 -30.0%
25,739 36,756 -30.0% 1,476
-15.4% 349,716 -15.0% Equities 1,122
1,602 -29.9% 24,693 35,243 -29.9% 1,426 -14.9% 337,862 -14.6%
Exchange-Traded Funds 12 22 -43.3% 274 483 -43.3% 13 -35.7% 3,191
-35.5% Structured Products 29 42 -30.1% 644 922 -30.1% 31 -26.1%
7,426 -25.8% Bonds 6 5 18.1% 127 108 18.1% 5 4.6% 1,236 5.0%
U.S. Cash Products (shares in millions) 5
1,585 2,108 -24.8% 33,284 44,272
-24.8% 1,699 -27.0% 390,714
-27.3% NYSE Listed (Tape A) Issues 4
Handled Volume 5 1,132 1,466 -22.8% 23,772 30,790 -22.8%
1,216 -25.7% 279,573 -26.1% Matched Volume 6 1,086 1,391 -22.0%
22,804 29,219 -22.0% 1,154 -25.6% 265,422 -25.9% Total NYSE Listed
Consolidated Volume 3,421 4,083 -16.2% 71,832 85,749 -16.2% 3,685
-17.0% 847,585 -17.3%
Share of Total Consolidated
Volume
Handled Volume 5 33.1% 35.9% -2.8% 33.1% 35.9% -2.8% 33.0% -3.9%
33.0% -3.9% Matched Volume 6 31.7% 34.1% -2.4% 31.7% 34.1% -2.4%
31.3% -3.6% 31.3% -3.6%
NYSE Arca, MKT and Regional (Tape
B) Listed Issues Handled Volume 5 235 368 -36.2% 4,936
7,738 -36.2% 250 -35.8% 57,456 -36.1% Matched Volume 6 217 333
-34.7% 4,564 6,988 -34.7% 226 -35.5% 51,956 -35.8% Total NYSE Arca
& MKT Listed Consolidated Volume 1,010 1,422 -29.0% 21,213
29,868 -29.0% 1,063 -29.2% 244,429 -29.5%
Share of Total
Consolidated Volume Handled Volume 5 23.3% 25.9% -2.6% 23.3%
25.9% -2.6% 23.5% -2.4% 23.5% -2.4% Matched Volume 6 21.5% 23.4%
-1.9% 21.5% 23.4% -1.9% 21.3% -2.1% 21.3% -2.1%
Nasdaq
Listed (Tape C) Issues Handled Volume 5 218 274 -20.3%
4,576 5,744 -20.3% 233 -22.5% 53,686 -22.9% Matched Volume 6 195
236 -17.6% 4,088 4,963 -17.6% 201 -22.5% 46,250 -22.9% Total Nasdaq
Listed Consolidated Volume 1,769 1,857 -4.7% 37,152 38,997 -4.7%
1,754 -14.8% 403,392 -15.2%
Share of Total Consolidated
Volume Handled Volume 5 12.3% 14.7% -2.4% 12.3% 14.7% -2.4%
13.3% -1.3% 13.3% -1.3% Matched Volume 6 11.0% 12.7% -1.7% 11.0%
12.7% -1.7% 11.5% -1.1% 11.5% -1.1%
Exchange-Traded
Funds 5,7 Handled Volume 5 225 355 -36.6% 4,727
7,453 -36.6% 235 -36.1% 54,030 -36.4% Matched Volume 6 209 320
-34.9% 4,381 6,728 -34.9% 212 -35.8% 48,824 -36.1% Total ETF
Consolidated Volume 987 1,400 -29.5% 20,728 29,409 -29.5% 1,028
-28.9% 236,429 -29.2%
Share of Total Consolidated
Volume Handled Volume 5 22.8% 25.3% -2.5% 22.8% 25.3% -2.5%
22.9% -2.6% 22.9% -2.6% Matched Volume 6 21.1% 22.9% -1.8% 21.1%
22.9% -1.8% 20.7% -2.2% 20.7% -2.2%
1
Data includes currency products.
2
Includes all trading activities for Bclear, NYSE Liffe's clearing
service for wholesale derivatives.
3
Includes trading in U.S. equity options contracts, not equity-index
options.
4
Includes all volume executed in NYSE Group crossing sessions.
5
Represents the total number of shares of equity securities and ETFs
internally matched on the NYSE Group's exchanges or routed to and
executed at an external market center. NYSE Arca routing includes
odd-lots.
6
Represents the total number of shares of equity securities and ETFs
executed on the NYSE Group's exchanges.
7
Data included in previously identified categories.
*
ADVs calculated with the appropriate
number of NYSE Liffe U.S. trading days. Source: NYSE Euronext,
Options Clearing Corporation and Consolidated Tape as reported for
equity securities. All trading activity is single-counted, except
European cash trading which is double counted to include both buys
and sells.
Grafico Azioni NYSE Group (NYSE:NYX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni NYSE Group (NYSE:NYX)
Storico
Da Set 2023 a Set 2024